Cargando…
Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing
BACKGROUND: Over 100 genes have been implicated in the aetiology of amyotrophic lateral sclerosis (ALS). A detailed understanding of their independent and cumulative contributions to disease burden may help guide various clinical and research efforts. METHODS: Using targeted high-throughput sequenci...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812897/ https://www.ncbi.nlm.nih.gov/pubmed/23881933 http://dx.doi.org/10.1136/jmedgenet-2013-101795 |
_version_ | 1782289019087880192 |
---|---|
author | Kenna, Kevin P McLaughlin, Russell L Byrne, Susan Elamin, Marwa Heverin, Mark Kenny, Elaine M Cormican, Paul Morris, Derek W Donaghy, Colette G Bradley, Daniel G Hardiman, Orla |
author_facet | Kenna, Kevin P McLaughlin, Russell L Byrne, Susan Elamin, Marwa Heverin, Mark Kenny, Elaine M Cormican, Paul Morris, Derek W Donaghy, Colette G Bradley, Daniel G Hardiman, Orla |
author_sort | Kenna, Kevin P |
collection | PubMed |
description | BACKGROUND: Over 100 genes have been implicated in the aetiology of amyotrophic lateral sclerosis (ALS). A detailed understanding of their independent and cumulative contributions to disease burden may help guide various clinical and research efforts. METHODS: Using targeted high-throughput sequencing, we characterised the variation of 10 Mendelian and 23 low penetrance/tentative ALS genes within a population-based cohort of 444 Irish ALS cases (50 fALS, 394 sALS) and 311 age-matched and geographically matched controls. RESULTS: Known or potential high-penetrance ALS variants were identified within 17.1% of patients (38% of fALS, 14.5% of sALS). 12.8% carried variants of Mendelian disease genes (C9orf72 8.78%; SETX 2.48%; ALS2 1.58%; FUS 0.45%; TARDBP 0.45%; OPTN 0.23%; VCP 0.23%. ANG, SOD1, VAPB 0%), 4.7% carried variants of low penetrance/tentative ALS genes and 9.7% (30% of fALS, 7.1% of sALS) carried previously described ALS variants (C9orf72 8.78%; FUS 0.45%; TARDBP 0.45%). 1.6% of patients carried multiple known/potential disease variants, including all identified carriers of an established ALS variant (p<0.01); TARDBP:c.859G>A(p.[G287S]) (n=2/2 sALS). Comparison of our results with those from studies of other European populations revealed significant differences in the spectrum of disease variation (p=1.7×10(−4)). CONCLUSIONS: Up to 17% of Irish ALS cases may carry high-penetrance variants within the investigated genes. However, the precise nature of genetic susceptibility differs significantly from that reported within other European populations. Certain variants may not cause disease in isolation and concomitant analysis of disease genes may prove highly important. |
format | Online Article Text |
id | pubmed-3812897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-38128972013-10-31 Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing Kenna, Kevin P McLaughlin, Russell L Byrne, Susan Elamin, Marwa Heverin, Mark Kenny, Elaine M Cormican, Paul Morris, Derek W Donaghy, Colette G Bradley, Daniel G Hardiman, Orla J Med Genet Screening BACKGROUND: Over 100 genes have been implicated in the aetiology of amyotrophic lateral sclerosis (ALS). A detailed understanding of their independent and cumulative contributions to disease burden may help guide various clinical and research efforts. METHODS: Using targeted high-throughput sequencing, we characterised the variation of 10 Mendelian and 23 low penetrance/tentative ALS genes within a population-based cohort of 444 Irish ALS cases (50 fALS, 394 sALS) and 311 age-matched and geographically matched controls. RESULTS: Known or potential high-penetrance ALS variants were identified within 17.1% of patients (38% of fALS, 14.5% of sALS). 12.8% carried variants of Mendelian disease genes (C9orf72 8.78%; SETX 2.48%; ALS2 1.58%; FUS 0.45%; TARDBP 0.45%; OPTN 0.23%; VCP 0.23%. ANG, SOD1, VAPB 0%), 4.7% carried variants of low penetrance/tentative ALS genes and 9.7% (30% of fALS, 7.1% of sALS) carried previously described ALS variants (C9orf72 8.78%; FUS 0.45%; TARDBP 0.45%). 1.6% of patients carried multiple known/potential disease variants, including all identified carriers of an established ALS variant (p<0.01); TARDBP:c.859G>A(p.[G287S]) (n=2/2 sALS). Comparison of our results with those from studies of other European populations revealed significant differences in the spectrum of disease variation (p=1.7×10(−4)). CONCLUSIONS: Up to 17% of Irish ALS cases may carry high-penetrance variants within the investigated genes. However, the precise nature of genetic susceptibility differs significantly from that reported within other European populations. Certain variants may not cause disease in isolation and concomitant analysis of disease genes may prove highly important. BMJ Publishing Group 2013-11 2013-07-23 /pmc/articles/PMC3812897/ /pubmed/23881933 http://dx.doi.org/10.1136/jmedgenet-2013-101795 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Screening Kenna, Kevin P McLaughlin, Russell L Byrne, Susan Elamin, Marwa Heverin, Mark Kenny, Elaine M Cormican, Paul Morris, Derek W Donaghy, Colette G Bradley, Daniel G Hardiman, Orla Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing |
title | Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing |
title_full | Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing |
title_fullStr | Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing |
title_full_unstemmed | Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing |
title_short | Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing |
title_sort | delineating the genetic heterogeneity of als using targeted high-throughput sequencing |
topic | Screening |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812897/ https://www.ncbi.nlm.nih.gov/pubmed/23881933 http://dx.doi.org/10.1136/jmedgenet-2013-101795 |
work_keys_str_mv | AT kennakevinp delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT mclaughlinrusselll delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT byrnesusan delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT elaminmarwa delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT heverinmark delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT kennyelainem delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT cormicanpaul delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT morrisderekw delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT donaghycoletteg delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT bradleydanielg delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing AT hardimanorla delineatingthegeneticheterogeneityofalsusingtargetedhighthroughputsequencing |